Dr Chodak reviews a new study on the 17-gene Genomic Prostate Score used for predicting prostate cancer outcomes.

Research finds that men have poor understanding of treatment outcomes for localized prostate cancer. It's a serious problem, says Dr Chodak.

How much physical activity is enough to reduce prostate cancer mortality? Dr Chodak reviews a new subanalysis of data from the Prostate Cancer Prevention Trial.

Dr Kenny Lin looks critically at recent statistical modeling data that he believes may set back prostate cancer care.

Dr Rob Glatter interviews Dr Neil Gandhi, medical director of the emergency department at Houston Methodist San Jacinto Hospital.

New, more effective antiandrogens are improving outcomes for men with newly diagnosed metastatic prostate cancer. The challenge is in choosing which to use, says Dr Chodak.

Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone.

New data make a very strong case for incorporating the 4K test into standard management of men advised to undergo prostate biopsy because of PSA test results, according to Dr Gerald Chodak.

How accurate is PSA density for predicting prostate cancer? Dr Chodak reviews new research in Urology comparing PSA density with PSA alone.

Dr Gerald Chodak reviews new data on active surveillance for low-risk prostate cancer and its effect on metastasis-free and prostate cancer-specific survival.